Paper Details

  1. Home
  2. Paper Details

Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study.

Author: KrammerGerhard, PorterBrian, RahmanProton, RichardsHanno B, SerioloBruno, TlustochowiczWitold, WidmerAlbert

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Secukinumab demonstrated improved efficacy in reducing disease activity over placebo as measured by DAS28 and other secondary endpoints.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy and safety of secukinumab, a fully human antiinterleukin-17A monoclonal antibody, administered with an intravenous (IV) or subcutaneous (SC) loading regimen versus placebo, in patients with active rheumatoid arthritis (RA). METHODS: In this phase II, double-blind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3899/jrheum.150117

データ提供：米国国立医学図書館（NLM）

Secukinumab for Rheumatoid Arthritis: Exploring Subcutaneous and Intravenous Loading Regimens

The treatment of [rheumatoid arthritis (RA)] often involves [immunomodulatory therapies]. This research evaluates the efficacy and safety of [secukinumab], a [monoclonal antibody] that targets [interleukin-17A], in patients with [active RA]. The authors conducted a [phase II clinical trial] to compare the effectiveness of two [loading dose regimens] of [secukinumab], [intravenous (IV)] and [subcutaneous (SC)].

Secukinumab: A Potential Therapeutic Option for Rheumatoid Arthritis

The study demonstrates that [secukinumab] effectively reduced [disease activity] in patients with [active RA], as measured by various [clinical outcome measures]. While the primary endpoint of [ACR20 response] was not met, the [secondary endpoints] showed significant improvement, suggesting the potential of [secukinumab] as a [therapeutic option] for this challenging disease.

Navigating Treatment Options for Rheumatoid Arthritis

This research contributes to the growing body of knowledge regarding [secukinumab] for [rheumatoid arthritis]. The findings highlight the potential of this [biological therapy] to improve [disease control] and alleviate [symptoms] in patients with [active RA]. As we continue to explore the [therapeutic landscape] of [rheumatoid arthritis], [secukinumab] remains a promising agent with potential to enhance the lives of those affected by this disease.

Dr.Camel's Conclusion

The desert is full of unexpected treasures, and this research offers a glimpse into the potential of [secukinumab] to treat [rheumatoid arthritis]. While further research is needed to fully understand its optimal use, the study suggests that this [biological therapy] holds promise for easing the burdens of this chronic disease. It's a reminder that the journey of medical discovery is an ongoing quest for new and better treatments, much like a camel traversing the desert in search of a hidden oasis.

Date :
  1. Date Completed 2016-12-26
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

26834211

DOI: Digital Object Identifier

10.3899/jrheum.150117

Related Literature

Article Analysis
・Effects of secukinumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.